📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 15:53
570 analysed today
570
Today
133,459
All-time analysed
40,112
Positive
6,281
Negative
79,251
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
32 announcements match the current filters (relevance ≥ 5).
Shilpa Medicare Q1 FY27: Record 469 Cr Revenue; Net Debt-to-EBITDA Drops to 1.3x
Shilpa Medicare reported its highest-ever quarterly revenue of 469 Cr (+43% YoY) and EBITDA of 139 Cr (+42% YoY) for Q1 FY27. The company has successfully deleveraged, reducing its net debt-to-EBITDA from 6.7x to 1.3x over three years, resulting in a credit rating upgrade to AA-. Management indicates the heavy investment phase is largely complete, with 'harvesting' beginning via complex launches like Rotigotine and Abraxane in FY28. Biologics revenue reached 50 Cr this quarter, with the Aflibercept biosimilar launch expected in India in FY27.
Confidence: HIGH
What changedThe company has transitioned from a high-debt API manufacturer to a diversified specialty pharma player with a strong balance sheet and a focus on complex generics and biologics.
Why it mattersThe reduction in leverage and improvement in ROCE (double-digit) combined with a 30% EBITDA margin indicates strong operating leverage as new facilities begin monetization.
Q1 FY27 Revenue: 469 CrEBITDA Margin: 30%Net Debt to EBITDA: 1.3xGross Margin: 71%Biologics Revenue (Q1): 50 CrRevenue vs TTM Revenue: 30.5%
📅 Short termThe stock may see positive momentum following record quarterly performance and the significant improvement in credit profile.
📈 Long termStructural shift towards high-value biologics, CDMO (25+ NCE programs), and complex transdermal patches provides a multi-year growth runway.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory risks associated with USFDA approvals for complex products
- Execution risk in global Phase II clinical studies for Nor-UDCA
Key Highlights
Record quarterly revenue of 469 Cr, representing 43% YoY growth and 42% EBITDA growth.
Net debt-to-EBITDA significantly reduced to 1.3x from 6.7x three years ago, with a credit rating upgrade to AA-.
Peptide manufacturing capacity expansion in India on track for commissioning by end of FY27.
Formulation division maintains high margins with over 50% captive API sourcing and 71% gross margins.
Biologics segment scaling with 50 Cr revenue in Q1 and 6 active NCE programs in the pipeline.
👀 What to Watch
Watch for the commissioning of the peptide plant by end-FY27 and the successful launch of Aflibercept in the Indian market during FY27 as key growth triggers.
43% Revenue Growth and Credit Rating Upgrade to AA- for Shilpa Medicare in Q1 FY27
Shilpa Medicare reported its highest-ever quarterly revenue of ₹469 Cr for Q1 FY27, a 43% YoY increase driven by growth across API, Formulations, and Biologicals. Profitability saw a significant jump with PAT rising 115% YoY to ₹101 Cr, while EBITDA margins remained robust at 30%. A key highlight is the credit rating upgrade from A+ to AA-, reflecting a strengthened balance sheet and improved return ratios, with adjusted ROCE reaching 18.3%. The company is actively expanding its oncology and peptide capacities, with a new oncology block slated for completion by the end of FY27.
Confidence: HIGH
What changedThe company has transitioned from a heavy investment phase to a monetization phase, evidenced by record quarterly financials and a significant credit rating upgrade.
Why it mattersThe 30% EBITDA margin and rising ROCE indicate strong operating leverage as complex products scale; the rating upgrade will likely reduce future borrowing costs.
Q1 Revenue: ₹469 CrRevenue vs TTM: 30.5%EBITDA Margin: 30%Adjusted ROCE: 18.3%Net Debt to EBITDA: 1.3x
📅 Short termThe stock is likely to react positively to the record earnings and the credit rating upgrade, which validates the company's financial turnaround.
📈 Long termStructural growth is supported by a strong pipeline in Biologics and Peptides, alongside a shift toward high-margin CDMO services and complex generics.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High R&D and compliance costs
- Execution risk in new capacity expansions
- Concentration in oncology and complex therapies
Key Highlights
Achieved record quarterly revenue of ₹469 Cr, representing a 43% YoY growth compared to ₹328 Cr in Q1 FY26.
PAT surged by 115% YoY to ₹101 Cr, up from ₹47 Cr in the same quarter last year.
Credit rating upgraded to AA- from A+, signaling improved financial stability and lower risk profile.
Adjusted ROCE (excluding Biologics/NBE) improved to 18.3% from 17.4% in FY26 and 3.4% in FY23.
Net Debt to EBITDA ratio further improved to 1.3x, down from 1.4x in FY26 and 6.7x in FY23.
👀 What to Watch
Watch for the execution and commissioning of the new oncology block by FY27-end and the commercial scale-up of the NorUDCA product in the Indian market.
Shilpa Medicare Q1 PAT Jumps 115% YoY to ₹100.9 Cr; EUR 7M Investment in Gate2Brain
Shilpa Medicare reported a strong performance for Q1 FY27, with consolidated revenue rising 44.9% YoY to ₹465.78 Cr. Net profit more than doubled YoY to ₹100.88 Cr, although it saw a slight sequential decline of 6.4% from the preceding March quarter. The company also formalized a strategic investment of up to EUR 7 million (~₹64 Cr) in Gate2Brain for project development. A final dividend record date has been set for September 4, 2026, ahead of the AGM on September 11.
Confidence: HIGH
What changedThe company has delivered a significant YoY earnings beat and formalized a strategic international investment in the biotech space.
Why it mattersThe strong YoY growth confirms the successful scale-up of the company's complex product portfolio and improved operating leverage, while the EUR 7M investment signals a continued focus on high-value R&D projects.
Q1 FY27 Consolidated Revenue: ₹465.78 CrQ1 FY27 Consolidated PAT: ₹100.88 CrYoY Revenue Growth: 44.9%Investment in Gate2Brain: EUR 7 millionInvestment vs TTM Revenue: ~4.2%
📅 Short termThe stock is likely to react positively to the triple-digit YoY profit growth and the clarity on the strategic investment.
📈 Long termThe company's shift toward niche, complex generics and biologics is reflecting in improved margins; long-term value depends on the successful monetization of these R&D-heavy investments.
⚠ Risk flags
- Sequential PAT decline of 6.4% compared to Q4 FY26
- High R&D and compliance costs associated with novel drug projects
Key Highlights
Consolidated Revenue increased 44.9% YoY to ₹465.78 Cr from ₹321.46 Cr in the year-ago period.
Net Profit (PAT) surged 115% YoY to ₹100.88 Cr compared to ₹46.89 Cr in Q1 FY26.
Strategic investment of up to EUR 7 million (~₹64 Cr) committed to Gate2Brain via subsidiary Shilpa Biocare.
Consolidated Profit Before Tax (PBT) stood at ₹98.06 Cr, representing a 21% margin.
Record date for the FY26 final dividend is fixed as September 4, 2026.
👀 What to Watch
Investors should monitor the commercialization progress of the Biologics and Transdermal segments, which are driving the current growth momentum. Watch for management commentary during the September 11 AGM regarding the execution timeline for the Gate2Brain partnership.
Shilpa Medicare Appoints Dr. Uday N. Harle as CEO of Biologics Subsidiary
Shilpa Medicare has appointed Dr. Uday N. Harle as the CEO of its wholly-owned subsidiary, Shilpa Biologicals Private Limited, effective August 03, 2026. Dr. Harle brings 24 years of global biopharmaceutical experience, including leadership roles at Amneal, Abbott, and Sun Pharma. This appointment is strategically significant as the company aims to monetize its biologics and fermentation facilities over the next 3-5 years. The subsidiary is central to Shilpa's growth strategy involving complex biosimilars and novel biologics for US and EU markets.
Confidence: HIGH
What changedAppointment of a highly experienced industry veteran as the CEO of the company's key biologics subsidiary.
Why it mattersBiologics is a core growth pillar for Shilpa Medicare; specialized leadership is essential to navigate high-entry-barrier markets and improve the company's current 5.0% ROCE through high-margin products.
Total Industry Experience: 24 yearsBiologics Experience: 18+ yearsBiosimilars Developed: 10+Novel Biologics Developed: 5+Effective Date: August 03, 2026
📅 Short termThe market is likely to view the addition of a seasoned leader for the biologics division positively, reinforcing confidence in the company's specialized growth path.
📈 Long termStructurally significant as the company scales its complex FDF and biologics portfolio to drive the targeted 20% growth rate and improve operating leverage.
⚠ Risk flags
- Execution risk in the highly regulated biologics segment
- High R&D and compliance costs associated with biosimilar development
Key Highlights
Dr. Uday N. Harle appointed as CEO of Shilpa Biologicals Private Limited effective August 03, 2026
Brings 24 years of biopharmaceutical experience, with 18+ years specifically in biologics and biosimilars
Track record includes contributing to the development of 10+ biosimilars and 5+ novel biologics
Previous leadership experience at major firms including Abbott, Amneal Group/Kashiv Biosciences, and Sun Pharma
Expertise covers the entire biologics value chain including USFDA, EMA, and MHRA regulatory approvals
👀 What to Watch
Watch for the execution timeline of the biologics monetization strategy and upcoming regulatory filings for biosimilars under the new leadership.
Rs 125 Cr Bank Facility Rated IND A+/Stable for Shilpa Biologicals Subsidiary
India Ratings and Research (Fitch Group) has assigned a credit rating of IND A+/Stable/IND A1+ to the bank loan facilities of Shilpa Biologicals Private Limited, a material subsidiary of Shilpa Medicare. The rating covers facilities totaling Rs 125 Cr (INR 1,250 million). This subsidiary is a core part of the company's strategy to monetize its Biologics and biosimilar investments. The stable outlook indicates a steady credit profile for the subsidiary's debt obligations.
Confidence: HIGH
What changedIndia Ratings has assigned formal credit ratings to the bank facilities of Shilpa Medicare's material subsidiary, Shilpa Biologicals Private Limited.
Why it mattersA strong credit rating (A+) for the biologics subsidiary ensures access to lower-cost debt financing, which is critical for the capital-intensive nature of biosimilar development and manufacturing.
Rated Facility Size: Rs 125 CrFacility vs Parent Net Worth: ~4.6%Facility vs TTM Revenue: ~8.1%Long-term Rating: IND A+/StableShort-term Rating: IND A1+
📅 Short termThe announcement is likely to be viewed neutrally to slightly positively by the market as it confirms the financial health of a key subsidiary.
📈 Long termThe rating supports the company's long-term structural shift toward complex biologics, providing a financial foundation for its 3-5 year monetization plan.
⚠ Risk flags
- Execution risk in the biologics segment
- Debt servicing dependency on subsidiary cash flows
Key Highlights
Assigned long-term rating of IND A+ with a Stable outlook
Assigned short-term rating of IND A1+ for bank facilities
Total rated facility size of Rs 125 Cr (INR 1,250 million)
Subsidiary is central to the company's Biologics and Albumin fermentation growth strategy
Parent company Shilpa Medicare has a consolidated net worth of Rs 2,714 Cr
👀 What to Watch
Investors should monitor the execution and monetization of the Biologics portfolio at this subsidiary, as the credit rating facilitates the necessary capital for these high-growth segments.
Resignation of CEO of Material Subsidiary Shilpa Biologicals Pvt Ltd
Dr. Sridevi Khambhampaty has resigned as the CEO of Shilpa Biologicals Private Limited, a material subsidiary of Shilpa Medicare, effective July 15, 2026. This subsidiary is a core component of the group's strategy to monetize biologics and fermentation facilities over the next 3-5 years. The resignation follows a three-month notice period initiated on April 15, 2026, cited as being for personal reasons. Given the company's focus on complex biosimilars like Adalimumab, leadership continuity in this specific division is critical for maintaining the projected 20% growth rate.
Confidence: HIGH
What changedThe Chief Executive Officer of Shilpa Medicare's material biologics subsidiary has stepped down after completing her notice period.
Why it mattersShilpa Biologicals is the primary vehicle for the company's high-margin biologics and fermentation business; leadership stability is vital for navigating complex regulatory approvals and clinical trials in the US and EU.
Effective Date of Cessation: 15 July 2026Notice Period Duration: 3 monthsTTM Revenue: Rs 1538 CrMarket Cap: Rs 10545 CrAdjusted ROCE (H1 FY26): 17.2%
📅 Short termThe stock may see neutral to cautious sentiment as the market assesses the impact of leadership change on the biologics division's execution timeline.
📈 Long termThe long-term trajectory depends on the successful monetization of the biologics and Albumin facilities, which are expected to contribute significantly over the next 3-5 years.
⚠ Risk flags
- Leadership transition risk in a specialized technical subsidiary
- Potential delay in biologics commercialization timelines
Key Highlights
Resignation of Dr. Sridevi Khambhampaty as CEO of Shilpa Biologicals effective July 15, 2026.
The resignation letter was submitted on April 15, 2026, fulfilling a 3-month notice period.
Shilpa Biologicals is classified as a material subsidiary, central to the group's Rs 1,538 Cr TTM revenue growth strategy.
Company is targeting a 20% growth rate driven by biologics and complex formulations.
Adjusted ROCE excluding biologics was 17.2% in H1 FY26, highlighting the investment phase of the subsidiary the CEO is exiting.
👀 What to Watch
Monitor the company's announcement regarding a successor for the CEO role at Shilpa Biologicals to ensure no disruption in the commercialization of the Albumin and biosimilar pipeline.
Upgraded to 'IND AA-' from 'IND A+' for Rs 485 Cr Bank Facilities
India Ratings and Research has upgraded the credit rating of Shilpa Medicare and its material subsidiary, Shilpa Pharma Lifesciences, to 'IND AA-/Stable' from 'IND A+/Positive'. The upgrade applies to bank loan facilities totaling Rs 485 Cr, reflecting improved operational performance and financial stability. This follows a significant rise in adjusted ROCE from 4% in FY23 to 17.2% in H1 FY26. With a very low debt-to-equity ratio of 0.05, the upgrade positions the company for potentially lower borrowing costs as it scales its Biologics and Albumin fermentation projects.
Confidence: HIGH
What changedThe company's credit rating was upgraded by one notch from IND A+ to IND AA- by India Ratings and Research.
Why it mattersAn upgrade to the 'AA' category signifies high safety and very low credit risk. This validates the company's improving operating leverage and financial health, likely leading to better terms for future debt requirements.
Total Rated Facilities: Rs 485 CrRated Facilities vs TTM Revenue: 31.5%New Rating: IND AA-/StableDebt-to-Equity Ratio: 0.05Adjusted ROCE (H1 FY26): 17.2%
📅 Short termThe upgrade is likely to be viewed positively by the market as it confirms the company's strengthening financial position and operational turnaround.
📈 Long termThe improved credit profile supports the company's long-term strategy of investing in complex generics and biologics, providing a stable financial foundation for capital-intensive projects.
⚠ Risk flags
- Execution risk in scaling new high-tech facilities
- Dependence on high-margin CDMO income which can be volatile
Key Highlights
Credit rating for Rs 110 Cr bank facilities of Shilpa Medicare upgraded to IND AA-/Stable from IND A+/Positive.
Material subsidiary Shilpa Pharma Lifesciences saw an upgrade for Rs 300 Cr in bank facilities to IND AA-.
Additional Rs 75 Cr in bank facilities for the subsidiary were assigned the new IND AA- rating.
The company maintains a very low Debt-to-Equity ratio of 0.05 on a net worth of Rs 2,714 Cr.
Adjusted ROCE (excluding Biologics/NBE) improved to 17.2% in H1 FY26 from 4% in FY23.
👀 What to Watch
Watch for a potential reduction in interest expenses in upcoming quarterly results due to the improved credit profile. Monitor the execution and monetization timeline of the Albumin fermentation facility, which is a key part of the company's growth strategy.
Shilpa Medicare Recommends ₹0.60 Dividend; to Acquire 28% Stake in Renewable Energy Firm
Shilpa Medicare has approved its audited FY26 financial results and recommended a final dividend of ₹0.60 per share (60% of face value). The company's subsidiaries are acquiring a 28% equity stake in Neo Green Power Project Private Limited to meet captive energy requirements, with completion expected by June 15, 2026. A notable highlight is the turnaround in its foreign associate, which contributed a profit of ₹18.21 Cr in FY26 compared to a loss of ₹2.5 Cr in the previous year. Additionally, the company is shifting its registered office from Karnataka to Maharashtra, subject to shareholder approval.
Confidence: HIGH
What changedThe company has transitioned from a loss-making associate to a profitable one, initiated a strategic investment in renewable energy for cost-saving, and proposed a corporate relocation to Maharashtra.
Why it mattersThe captive power investment (28% stake) is a margin-protection move against rising energy costs. The associate profit turnaround significantly impacts the consolidated bottom line, which saw TTM PAT at ₹243 Cr.
Final Dividend: ₹0.60 per shareStake in Neo Green Power: 28%Associate Profit Contribution: ₹18.21 CrBonus Issue Ratio: 1:1 (Oct 2025)TTM Revenue: ₹1538 Cr
📅 Short termThe stock may see positive sentiment due to the dividend declaration and the strong turnaround in associate profits reported in the annual results.
📈 Long termThe shift toward captive renewable energy and the scale-up of complex FDF products in US/EU markets remain structural drivers for margin expansion beyond the current 28.2% OPM.
⚠ Risk flags
- Regulatory approval for shifting registered office
- Execution risk in renewable energy project completion
Key Highlights
Recommended a final dividend of ₹0.60 per equity share (60% of face value ₹1) for FY 2025-26.
Subsidiaries to acquire a 28% equity stake in Neo Green Power Project Private Limited by June 15, 2026, for captive power consumption.
Foreign associate performance improved significantly, contributing ₹18.21 Cr profit in FY26 vs a ₹2.5 Cr loss in FY25.
Approved shifting of the registered office and those of four wholly-owned subsidiaries from Karnataka to Maharashtra.
Adjusted EPS for all comparative periods following a 1:1 bonus share allotment completed in October 2025.
👀 What to Watch
Investors should monitor the completion of the renewable energy investment by mid-June 2026 and track if the shift to Maharashtra leads to any operational or tax efficiencies. The turnaround in the foreign associate is a key positive for consolidated margins.
$4.1B Market Opportunity: Shilpa Medicare Partners with Orion for Nivolumab Biosimilar in Europe
Shilpa Medicare's subsidiary, Shilpa Biologicals, has entered into a strategic co-development and supply agreement with Finland-based Orion Corporation for a Nivolumab biosimilar. Nivolumab is a blockbuster cancer immunotherapy with European sales reaching approximately $4.1 billion in 2025. Under the deal, Shilpa will lead development and exclusive manufacturing from its Dharwad facility, while Orion manages European commercialization. Shilpa is set to receive development and regulatory milestone payments in addition to long-term supply revenue.
Confidence: HIGH
What changedShilpa has secured a high-value partnership for a specific blockbuster biosimilar, moving from general capacity expansion to a defined product-market strategy in Europe.
Why it mattersThis validates Shilpa's biologics manufacturing capabilities and provides a clear monetization path for its Dharwad facility in a multi-billion dollar therapy area (immuno-oncology).
Nivolumab European Market (2025): $4.1 billionOrion Net Sales (2025): EUR 1,890 millionTTM Revenue: Rs 1538 CrMarket Cap: Rs 9429 CrMilestone Payments: not disclosed
📅 Short termThe announcement is likely to be viewed positively by the market as it provides visibility into the biologics segment's future revenue streams and validates the company's R&D focus.
📈 Long termThis represents a structural shift toward high-margin biologics and biosimilars, which could significantly improve ROCE (currently 5.0%) as the Dharwad facility scales up.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory approval risks in the EU
- Competition from other biosimilar manufacturers
- Execution risk in complex biologics development
Key Highlights
Targeting a European Nivolumab market valued at approximately $4.1 billion (USD) as of 2025.
Shilpa to receive milestone payments for development and regulatory achievements plus long-term supply revenue.
Manufacturing will be exclusively handled at Shilpa's advanced EU-GMP biologics facility in Dharwad, India.
Partner Orion Corporation is a major Nordic player with 2025 net sales of EUR 1,890 million.
The agreement leverages the upcoming loss of exclusivity for the originator Nivolumab in the European market.
👀 What to Watch
Watch for updates regarding clinical trial progress and the specific timeline for European regulatory filings, as these will trigger milestone payments.
Shilpa Medicare Subsidiary Settles Rs 20.13 Cr Legal Dispute for Rs 9 Crore
Shilpa Medicare's material subsidiary, Shilpa Biologicals Pvt. Ltd, has reached an amicable settlement with Sartorius Stedim India Pvt. Ltd. The dispute, which originally involved a claim of Rs 20.13 crore plus interest, has been resolved for a final payment of Rs 9 crore. The settlement agreement was executed on June 23, 2026, before the Commercial Court in Bengaluru. This resolution effectively ends the litigation and limits the financial impact to the agreed settlement amount.
Key Highlights
Settlement amount fixed at Rs 9.00 crore, significantly lower than the original claim of Rs 20.13 crore
Agreement executed on June 23, 2026, before the Hon’ble XI Addl. City Civil and Sessions Court, Bengaluru
The dispute involved Shilpa Biologicals Pvt. Ltd, a material subsidiary of Shilpa Medicare Limited
Financial impact on the company is strictly limited to the Rs 9 crore settlement payment
👀 What to Watch
Investors should view this as a positive development as it resolves a legal overhang at less than 50% of the original claimed amount. No further litigation risk remains regarding this specific dispute with Sartorius.
Shilpa Medicare Commissions Integrated ADC GMP Manufacturing Facility for Global Markets
Shilpa Medicare's subsidiary, Shilpa Biologicals, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP manufacturing facility in Dharwad. This facility is one of the very few in India to offer fully integrated, end-to-end ADC Drug Substance development, including payload synthesis and monoclonal antibody production. It is designed to meet stringent US FDA and EMA standards, targeting the high-growth global oncology CDMO market. The move leverages the company's 25-year expertise in high-potency compounds to provide a one-stop solution for advanced oncology treatments.
Key Highlights
Commissioned one of India's few integrated ADC Drug Substance GMP manufacturing facilities in Dharwad.
Facility designed to comply with US FDA, EMA, and other major global health authority requirements.
Provides end-to-end capabilities including payload synthesis, linker development, and mAb production.
Leverages 25 years of deep-rooted expertise in High Potency API (HPAPI) manufacturing.
Positions the company as a specialized CDMO partner for global biotech and pharmaceutical firms.
👀 What to Watch
This expansion into high-value biologics and specialized CDMO services is a significant positive for long-term margins. Investors should monitor the ramp-up of capacity utilization and the acquisition of international regulatory certifications.
Shilpa Medicare to Acquire 30.4% Stake in Gate2Brain for Euro 7 Million
Shilpa Medicare's subsidiary, Shilpa Biocare, is entering a strategic equity partnership to acquire a 30.4% stake in Spanish biotech firm Gate2Brain for Euro 7 million. The deal involves Euro 0.5 million in cash, Euro 5.5 million in equity for services, and Euro 1 million for project development. This partnership focuses on advancing G2B-002, a brain cancer therapy with Orphan Drug Designation from both the US FDA and EMA. Shilpa will serve as the exclusive CMC and manufacturing partner, targeting high-value oncology markets such as Glioblastoma, which is projected to reach USD 6.48 billion by 2035.
Key Highlights
Acquisition of a 30.4% equity stake in Gate2Brain for a total contribution of Euro 7 million.
Lead candidate G2B-002 has received Orphan Drug Designation (ODD) from both the U.S. FDA and EMA.
Investment structure includes Euro 5.5 million as 'equity for services', leveraging Shilpa's manufacturing capabilities.
Proprietary MiniAp4 peptide shuttle technology demonstrated up to 100-fold greater brain drug transport in preclinical models.
First-in-human trials for the lead brain cancer asset are anticipated to commence by FY28.
👀 What to Watch
Investors should monitor the progress of clinical trials for G2B-002 as a long-term value driver, while noting that the 'equity for services' model de-risks the cash outflow for Shilpa Medicare.
Shilpa Medicare Unit VI Receives USFDA Form 483 with 5 Procedural Observations
Shilpa Medicare's Bengaluru facility (Unit VI) underwent a USFDA Pre-Approval Inspection from May 25 to May 29, 2026. The inspection concluded with the issuance of Form 483 containing 5 procedural observations, none of which are related to data integrity or are repeat findings. The facility specializes in oral dispersible films and transdermal patches and already holds VAI status from previous audits. Management expects no material impact on current operations and plans to respond within the stipulated timeline.
Key Highlights
USFDA conducted a Pre-Approval Inspection at the Bengaluru Unit VI from May 25-29, 2026
The inspection resulted in Form 483 with 5 procedural observations and zero data integrity issues
Unit VI holds existing accreditations from EMA (Europe), MHRA (UK), TGA (Australia), and SFDA (Saudi Arabia)
Management confirmed no material impact on current business operations or existing supplies
👀 What to Watch
Investors should monitor the company's response to the USFDA and the final classification of the audit. The absence of data integrity issues suggests a lower risk of severe regulatory action like a Warning Letter.
Shilpa Medicare Reports Record FY26 Revenue of ₹1,549 Cr; Adjusted PAT Surges 135% YoY
Shilpa Medicare delivered a strong FY26 performance with record revenues of ₹1,549 crores and an EBITDA of ₹445 crores, driven by robust growth in formulations and biologics. The company's adjusted PAT grew by 135% to ₹232 crores, while adjusted ROCE improved significantly to 17.4% from 4% in FY23. Management is pivoting towards complex products, including ADCs and biosimilars, with key launches like Aflibercept and Rotigotine planned for FY27.
Key Highlights
Full-year FY26 revenue grew 18% to ₹1,549 crores, with Q4 revenue hitting a record ₹439 crores.
Adjusted PAT (excluding exceptional gains) jumped 135% YoY to ₹232 crores for the full year.
Formulation business (excluding licensing) grew 75% for the year, with European revenues doubling to over ₹200 crores.
Biologics segment revenue doubled to ₹150 crores, supported by strong CDMO deal momentum.
Adjusted ROCE improved from 4% in FY23 to 17.4% in FY26, reflecting significantly better operating leverage.
👀 What to Watch
Investors should monitor the successful commercialization of high-value products like Aflibercept and Rotigotine in FY27. The company's transition to a complex formulation and biologics platform supports long-term margin expansion and justifies a positive outlook.
Shilpa Medicare FY26 Revenue Grows 18% to ₹1,549 Cr; Adj. PAT Surges 135%
Shilpa Medicare reported a strong financial performance for FY26, with consolidated revenue reaching INR 1,549 crores, an 18% YoY increase. The company's profitability saw a significant boost, with EBITDA growing 30% to INR 445 crores and Adjusted PAT surging 135% to INR 232 crores. The Formulations segment was a key growth driver, increasing 30% YoY to INR 618 crores, supported by the successful launch of NorUDCA for NAFLD. Operational efficiency improved as EBITDA margins expanded to 29% and the Net Debt to EBITDA ratio decreased to 1.4x.
Key Highlights
FY26 Revenue grew 18% YoY to INR 1,549 crores; Q4 FY26 revenue rose 30% to INR 439 crores.
Adjusted PAT for FY26 increased by 135% YoY to INR 232 crores, demonstrating strong bottom-line acceleration.
EBITDA margins expanded by 300 bps to 29% for FY26, driven by a favorable product mix and operating leverage.
Formulations revenue grew 30% YoY in FY26, with EU revenue crossing the INR 200 crore milestone.
Net Debt to EBITDA ratio improved from 1.6x in FY25 to 1.4x in FY26, reflecting better capital efficiency.
👀 What to Watch
Investors should note the strong turnaround in profitability and the scaling of high-margin formulations and biologics segments. The stock remains a positive watch given the upcoming transdermal patch launches in the EU and US.
Shilpa Medicare Recommends ₹0.60 Dividend and 28% Stake Acquisition in Neo Green Power
Shilpa Medicare's board has recommended a final dividend of ₹0.60 per share (60% of face value) for the financial year 2025-26. In a strategic move, the company's subsidiaries will also acquire a 28% equity stake in Neo Green Power Project Private Limited for ₹4.44 crore to meet captive renewable energy requirements. Additionally, the company has approved its audited FY26 financial results and proposed shifting its registered office from Karnataka to Maharashtra. These developments indicate a focus on shareholder returns and operational cost optimization through green energy.
Key Highlights
Recommended a final dividend of ₹0.60 (60%) per equity share of face value ₹1 for FY 2025-26.
Subsidiaries to acquire a 28% stake in Neo Green Power Project Private Limited for ₹4.44 crore.
The acquisition is intended to secure renewable energy for captive power consumption in subsidiaries.
Approved audited standalone and consolidated financial statements for FY ended March 31, 2026.
Proposed shifting of the registered office from Raichur, Karnataka to the State of Maharashtra.
👀 What to Watch
Investors should monitor the upcoming AGM for dividend approval and the impact of the renewable energy investment on long-term operating margins. The shift to Maharashtra suggests a strategic relocation to a major industrial hub which may offer better administrative synergies.
Shilpa Medicare Recommends 60% Dividend; To Acquire 28% Stake in Neo Green Power
Shilpa Medicare has recommended a final dividend of Re. 0.60 per share for FY 2025-26, representing 60% of the face value. The company is also investing ₹4.44 Crore for a 28% stake in Neo Green Power Project Private Limited to meet captive energy needs for its subsidiaries. Furthermore, the board approved shifting the registered office from Karnataka to Maharashtra, subject to shareholder approval. These moves indicate a focus on operational efficiency through renewable energy and corporate restructuring.
Key Highlights
Recommended a final dividend of Re. 0.60 (60%) per equity share of face value Re. 1 for FY 2025-26.
Investing ₹4.44 Crore to acquire a 28% equity stake in Neo Green Power Project Private Limited.
The acquisition is intended for captive power consumption to optimize energy costs across subsidiaries.
Approved shifting the registered office and those of four wholly-owned subsidiaries from Karnataka to Maharashtra.
Appointed M/s ANEJA ASSOCIATES as Internal Auditors and M/s. V.J. Talati & Co. as Cost Auditors for FY 2026-27.
👀 What to Watch
The dividend and strategic investment in renewable energy are positive signals for long-term cost management. Investors should maintain their positions while monitoring the impact of the corporate relocation on administrative efficiency.
Shilpa Medicare Appoints Dr. Vellaian Karuppiah as COO-Formulations; 33+ Years Experience
Shilpa Medicare has appointed Dr. Vellaian Karuppiah as the Chief Operating Officer (COO) for its Formulations division, effective April 23, 2026. Dr. Karuppiah is a pharmaceutical veteran with over 33 years of experience, having held senior leadership roles at major companies including Gland Pharma, Dr. Reddy’s Laboratories, and Strides Group. His deep expertise in R&D, manufacturing operations, and regulatory affairs is expected to drive operational excellence in the company's formulations business. This strategic hire aims to strengthen the company's growth trajectory and enhance global competitiveness.
Key Highlights
Dr. Vellaian Karuppiah appointed as COO - Formulations effective April 23, 2026
Brings over 33 years of extensive experience across the pharmaceutical value chain
Previous leadership roles at Gland Pharma, Strides Group, Dr. Reddy’s, and Teva (Actavis)
Holds a Doctorate in Pharmacy and Executive Management qualifications from Tier-1 institutions
Mandate includes strengthening manufacturing efficiency, quality systems, and R&D integration
👀 What to Watch
Investors should view this as a positive development as the company brings in high-caliber talent from top-tier pharma firms to lead its formulations business. Monitor for improvements in operational margins and execution in the formulations segment over the coming quarters.
Shilpa Medicare Receives NCLT Approval for Merger with Shilpa Therapeutics
The National Company Law Tribunal (NCLT), Bengaluru Bench, has sanctioned the Scheme of Amalgamation between Shilpa Therapeutics Private Limited and its parent company, Shilpa Medicare Limited. As the transferor is a wholly-owned subsidiary, no new shares will be issued, and the existing share capital of the subsidiary will stand cancelled. The merger, with an appointed date of April 1, 2023, aims to streamline corporate structure and integrate operations. The company is now in the process of filing the certified order with the Registrar of Companies to make the merger effective.
Key Highlights
NCLT Bengaluru Bench approved the merger of Shilpa Therapeutics (subsidiary) into Shilpa Medicare (parent) on February 27, 2026.
No new shares will be issued as the transferor is a 100% subsidiary of the transferee company.
The appointed date for the amalgamation is fixed as April 1, 2023.
Statutory dues of ₹61.17 lakhs for the subsidiary and ₹3.59 crores for the parent were noted as of FY24 for settlement.
The authorized share capital of both entities will be clubbed, and all employees will be absorbed into Shilpa Medicare.
👀 What to Watch
Investors should view this as a positive step toward corporate simplification and operational synergy. Since no new shares are being issued, there is no equity dilution for existing shareholders.
Shilpa Medicare Subsidiary Partners with SteinCares to Launch Biosimilar in Latin America
Shilpa Medicare's subsidiary, Shilpa Biologicals, has entered into a strategic licensing agreement with SteinCares to commercialize a biosimilar across Latin America. SteinCares will hold exclusive rights to register and distribute the product across 30 countries in the region, while Shilpa will handle development and long-term manufacturing from its Dharwad facility. This agreement marks Shilpa Biologicals' first entry into the Latin American market, a significant step in its global biosimilar expansion. The partnership leverages SteinCares' 45 years of regional expertise to provide cost-effective specialty treatments.
Key Highlights
Exclusive licensing agreement with SteinCares for biosimilar distribution in 30 Latin American countries.
Shilpa Biologicals to provide long-term commercial manufacturing from its Dharwad, India facility.
Marks the first product from this strategic partnership and Shilpa's entry into the Latin American market.
SteinCares brings over 45 years of experience in specialty healthcare and biosimilars in the region.
Focuses on high-value therapeutic areas including immunology, oncology, and ophthalmics.
👀 What to Watch
Investors should view this as a positive step towards diversifying revenue streams and entering high-growth international markets. Monitor for future regulatory approvals and product launch timelines in specific Latin American countries to gauge revenue impact.
